Clinical trials: Mesenchymal Stem Cell
Acute Myocardial Infarction
Safety Study of Allogeneic Mesenchymal Precursor Cell Infusion in Myocardial Infarction
This was a double-blind, randomized, placebo-controlled study that was designed to enroll a total of 225 participants with de novo anterior wall acute ST-segment elevation myocardial infarction (STEMI) due to a lesion of the left…
- Trial name
- AMICI (NCT01781390)
- Testing
- Mesenchymal Precursor Cells (MPC) 12.5 M, Mesenchymal Precursor Cells (MPC) 25 M
- Volunteers
- 106 people
- Sponsor
- Mesoblast, Inc.
Multiple Sclerosis
Multi-Center Study Safety of Adipose Derived Mesenchymal Stem Cells for the Treatment of Multiple Sclerosis
The intent of this clinical study is to answer the questions: 1) is the proposed treatment safe and 2) is treatment effective in improving the disease pathology of patients with Multiple Sclerosis and clinical outcomes.
- Trial name
- NCT02326935
- Testing
- Autologous adipose derived mesenchymal cells
- Where
- Cayman Islands
- Volunteers
- 2 people
- Sponsor
- American CryoStem Corporation
Solid Tumor, Metastatic Cancer
Phase I Dose Escalation Study of AB-16B5 in Subjects With an Advanced Solid Malignancy
This is a Phase 1 clinical study to investigate the safety, pharmacokinetics and pharmacodynamics of AB-16B5 in patients with an advanced solid malignancy.
- Trial name
- NCT02412462
- Testing
- AB-16B5
- Where
- Canada
- Volunteers
- 15 people
- Sponsor
- Alethia Biotherapeutics
Knee Osteoarthritis
Clinical Trial to Evaluate Efficacy and Safety of SMUP-IA-01 in Patients With Knee Osteoarthritis
This clinical trial is for patients who have been diagnosed with Kellgren-Lawrence (K\&L) Grade 2 or 3 knee osteoarthritis on radiographic examination.
- Trial name
- NCT05182034
- Testing
- SMUP-IA-01(low dose), SMUP-IA-01(mid dose), Active Control Group Sodium chloride
- Where
- 5 sites in South Korea
- Volunteers
- 94 people
- Sponsor
- Medipost Co Ltd.
Knee Osteoarthritis
Efficacy of Bone-marrow-derived and Placenta-derived Multipotent Mesenchymal Stem / Stromal Cells for Osteoarthritis
To define the clinical effects of intra-articular transplantation of bone-marrow-derived (BM-MMSCs) and placenta-derived multipotent mesenchymal stem / stromal cells (P-MMSCs) for knee osteoarthritis.
- Trial name
- NCT04453111
- Testing
- Placenta-derived MMSCs, Bone marrow-derived MMSCs, Hyalgan 20 mg in 2 ML Prefilled Syringe
- Where
- Ukraine
- Volunteers
- 45 people
- Sponsor
- Institute of Cell Therapy
Liver Cirrhoses
Umbilical Cord Mesenchymal Stem Cell for Liver Cirrhosis Patient Caused by Hepatitis B
The study aims to evaluate the effect of allogeneic mesenchymal stem cell therapy on patients who suffered from liver cirrhosis caused by Hepatitis B.
- Trial name
- NCT04357600
- Testing
- Allogeneic Umbilical Cord Mesenchymal Stem Cell
- Where
- Indonesia
- Volunteers
- 12 people
- Sponsor
- PT. Prodia Stem Cell Indonesia
Degenerative Osteoarthritis, Defect of Articular Cartilage
Follow-Up Study of CARTISTEM® Versus Microfracture for the Treatment of Knee Articular Cartilage Injury or Defect
This is a long term follow-up study to investigate the safety and efficacy of CARTISTEM®, human umbilical cord blood-derived mesenchymal stem cells, in repair of cartilage injury or defects, compared with microfracture.
- Trial name
- NCT01626677
- Testing
- CARTISTEM, Microfracture
- Where
- 10 sites in South Korea
- Volunteers
- 103 people
- Sponsor
- Medipost Co Ltd.
Knee Osteoarthritis
Follow-up Study for Participants of Jointstem Phase 3 Clinical Trial
The purpose of this follow-up study is to investigate the efficacy and safety of autologous Adipose Tissue derived Mesenchymal stem cells (JOINTSTEM®) in patient with severe Knee Osteoarthritis.
- Trial name
- NCT04427930
- Testing
- JOINTSTEM
- Where
- 4 sites in South Korea
- Volunteers
- 129 people
- Sponsor
- R-Bio
Knee Osteoarthritis
Autologous Adipose Tissue Derived Mesenchymal Stem Cells Therapy for Patients With Knee Osteoarthritis
Two injections in total and 3 ml autologous adipose-tissue-derived stem cells(haMSCs) for each injection; time-points for intervention: 1) initial injection; 2) 3 weeks following initial injection.
- Trial name
- NCT01809769
- Testing
- Mesenchymal stem cells low-dose group, Mesenchymal stem cells mid-dose group, Mesenchymal stem cells high-dose group
- Where
- China
- Volunteers
- 18 people
- Sponsor
- Shanghai AbelZeta Ltd.
Acute Myocardial Infarction
To Evaluate the Efficacy and Safety of Hearticelgram®-AMI in Patients With Acute Myocardial Infarction.
Through the injection of Hearticellgram-AMI into acute myocardial infarction patients who are the primary targets of the drug, long term efficacy in the improvement of the left ventricle ejection fraction upon the first cell…
- Trial name
- NCT01652209
- Testing
- Hearticellgram-AMI
- Where
- 10 sites in South Korea
- Volunteers
- 90 people
- Sponsor
- Pharmicell Co., Ltd.
Chronic Obstructive Pulmonary Disease
Treatment of Chronic Obstructive Pulmonary Disease by Infusion of Allogenic Mesenchymal Stem Cells
This phase II study is a randomized, placebo-controlled, double-blind study to evaluate the safety and efficacy of UMC119-06-05 compared to placebo in treating subjects with moderate to severe COPD.
- Trial name
- NCT06491043
- Testing
- UMC119-06-05
- Where
- 2 sites in Taiwan
- Volunteers
- 90 people
- Sponsor
- Meribank Biotech Co., Ltd.
Spinal Cord Injury
Safety and Feasibility Study of Cell Therapy in Treatment of Spinal Cord Injury
Human Umbilical Cord-derived Mesenchymal Stem Cells (UC-MSC) and Bone Marrow Mononuclear Cells (BMMC) from the patient injected into the spinal fluid intrathecally and injected intravenously (IV) is a safe and therapeutic…
- Trial name
- NCT02237547
- Testing
- Intravenous and intrathecal human umbilical cord tissue-derived mesenchymal stem cells and bone marrow mononuclear cells
- Where
- Panama
- Volunteers
- healthy volunteers welcome
- Sponsor
- Translational Biosciences
Bronchopulmonary Dysplasia
Mesenchymal Stem Cells for Prevention of Bronchopulmonary Dysplasia in Infants
The clinical study with UMC119-01 is designed to investigate the safety in patients with bronchopulmonary dysplasia ("BPD"). This will be a dose escalation, open-label, single-center study in infants at high risk for BPD.
- Trial name
- NCT03631420
- Testing
- Human Umbilical Cord Derived-Mesenchymal Stem Cells
- Where
- Taiwan
- Volunteers
- 9 people
- Sponsor
- Meridigen Biotech Co., Ltd.
Retinitis Pigmentosa
Safety Issues of Peribulbar Injection of UC-MSC in Patients With Retinitis Pigmentosa
The study will perform UC-MSCs and CM transplantation. The first group will be injected by UCMSC+NaCl. the 2nd group will be injected by UC-MSC+CM. the 3rd group will be injected by CM. Each group consists of 6 subjects.
- Trial name
- RP (NCT04315025)
- Testing
- Umbilical Cord Mesenchymal Stem Cell (UC-MSC), Conditioned Medium (CM)
- Where
- 2 sites in Indonesia
- Volunteers
- 18 people
- Sponsor
- PT. Prodia Stem Cell Indonesia